Takeda Pharmaceutical Company Limited (LON:0A87)
15.89
0.00 (0.00%)
At close: Jan 20, 2026
LON:0A87 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 4,464,578 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 | 3,197,812 | |
Revenue Growth (YoY) | -2.50% | 7.45% | 5.87% | 12.85% | 11.61% | -2.84% |
Cost of Revenue | 1,539,164 | 1,571,419 | 1,431,505 | 1,253,163 | 1,127,308 | 1,013,655 |
Gross Profit | 2,925,414 | 3,010,132 | 2,832,257 | 2,774,315 | 2,441,698 | 2,184,157 |
Selling, General & Admin | 1,088,051 | 1,104,732 | 1,053,819 | 997,234 | 886,327 | 875,514 |
Research & Development | 696,610 | 730,226 | 728,617 | 633,325 | 526,087 | 455,765 |
Amortization of Goodwill & Intangibles | 533,435 | 548,186 | 521,525 | 485,102 | 418,789 | 405,229 |
Other Operating Expenses | 4,117 | 64,052 | 28,821 | 38,987 | 10,433 | 23,602 |
Operating Expenses | 2,322,213 | 2,447,196 | 2,332,782 | 2,154,648 | 1,841,636 | 1,760,110 |
Operating Income | 603,201 | 562,936 | 499,475 | 619,667 | 600,062 | 424,047 |
Interest Expense | -130,487 | -130,487 | -115,392 | -116,973 | -122,432 | -130,806 |
Interest & Investment Income | 198,203 | 19,983 | 11,628 | 5,781 | 4,763 | 2,153 |
Earnings From Equity Investments | -2,603 | -3,986 | 6,473 | -8,630 | -15,367 | 76 |
Currency Exchange Gain (Loss) | 786 | 786 | -13,612 | -9,729 | -3,903 | -15,575 |
Other Non Operating Income (Expenses) | -159,648 | -24,865 | -31,520 | 3,975 | -26,119 | 1,118 |
EBT Excluding Unusual Items | 509,452 | 424,367 | 357,052 | 494,091 | 437,004 | 281,013 |
Merger & Restructuring Charges | -128,133 | -128,133 | -81,358 | -59,234 | -83,836 | -115,875 |
Gain (Loss) on Sale of Investments | -38,285 | -18,885 | - | 22,416 | 8,482 | - |
Gain (Loss) on Sale of Assets | 28,461 | 10,561 | 7,975 | 8,901 | 8,164 | 235,117 |
Asset Writedown | -156,679 | -103,379 | -146,047 | -62,484 | -54,421 | -17,521 |
Legal Settlements | - | - | -45,212 | -16,455 | -20,319 | -17,401 |
Other Unusual Items | -9,447 | -9,447 | -39,619 | -12,145 | 7,497 | 902 |
Pretax Income | 205,369 | 175,084 | 52,791 | 375,090 | 302,571 | 366,235 |
Income Tax Expense | 92,184 | 66,941 | -91,406 | 58,052 | 72,405 | -9,936 |
Earnings From Continuing Operations | 113,185 | 108,143 | 144,197 | 317,038 | 230,166 | 376,171 |
Minority Interest in Earnings | -259 | -215 | -130 | -21 | -107 | -166 |
Net Income | 112,926 | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 |
Net Income to Common | 112,926 | 107,928 | 144,067 | 317,017 | 230,059 | 376,005 |
Net Income Growth | -45.73% | -25.09% | -54.55% | 37.80% | -38.81% | 749.90% |
Shares Outstanding (Basic) | 1,575 | 1,579 | 1,564 | 1,552 | 1,564 | 1,562 |
Shares Outstanding (Diluted) | 1,602 | 1,605 | 1,580 | 1,570 | 1,577 | 1,574 |
Shares Change (YoY) | 0.25% | 1.58% | 0.67% | -0.46% | 0.23% | 0.47% |
EPS (Basic) | 71.69 | 68.36 | 92.09 | 204.29 | 147.14 | 240.72 |
EPS (Diluted) | 70.47 | 67.23 | 91.16 | 201.94 | 145.87 | 238.96 |
EPS Growth | -45.86% | -26.25% | -54.86% | 38.44% | -38.96% | 745.88% |
Free Cash Flow | 1,010,628 | 856,387 | 540,924 | 836,499 | 999,853 | 899,725 |
Free Cash Flow Per Share | 630.67 | 533.47 | 342.28 | 532.85 | 633.95 | 571.78 |
Dividend Per Share | 198.000 | 196.000 | 188.000 | 180.000 | 180.000 | 180.000 |
Dividend Growth | 3.13% | 4.25% | 4.44% | - | - | - |
Gross Margin | 65.53% | 65.70% | 66.43% | 68.88% | 68.41% | 68.30% |
Operating Margin | 13.51% | 12.29% | 11.71% | 15.39% | 16.81% | 13.26% |
Profit Margin | 2.53% | 2.36% | 3.38% | 7.87% | 6.45% | 11.76% |
Free Cash Flow Margin | 22.64% | 18.69% | 12.69% | 20.77% | 28.02% | 28.14% |
EBITDA | 1,273,957 | 1,233,262 | 1,143,936 | 1,284,067 | 1,183,213 | 983,718 |
EBITDA Margin | 28.54% | 26.92% | 26.83% | 31.88% | 33.15% | 30.76% |
D&A For EBITDA | 670,756 | 670,326 | 644,461 | 664,400 | 583,151 | 559,671 |
EBIT | 603,201 | 562,936 | 499,475 | 619,667 | 600,062 | 424,047 |
EBIT Margin | 13.51% | 12.29% | 11.71% | 15.39% | 16.81% | 13.26% |
Effective Tax Rate | 44.89% | 38.23% | - | 15.48% | 23.93% | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.